Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos
  3. Sarcoma Videos

Regorafenib as Maintenance Therapy after First-Line Doxorubicin-based Chemotherapy in Advanced Soft Tissue Sarcoma

Breaking Science in Sarcoma Video Series

Login to get immediate access to this content.

Login

Speaker: Nicolas Penel, France

Abstract discussed:

  • 1718O - EREMISS Trial: a double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of Regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts): Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

Related Videos

Screenshot Hans Gelderblom
Screenshot Jennifer CHAN
Screenshot Alexander DRILLON
Screenshot Jeffrey CRAWFORD

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.